Vasoactive intestinal polypeptide stimulation of prolactin release and renin activity in normal man and patients with hyperprolactinaemia: effects of pretreatment with bromocriptine and dexamethazone.

Lightman SL, Unwin RJ, Graham K, Dimaline R, McGarrick G

European journal of clinical investigation1 Dec 1984Cited by 5 (Europe PMC)

PMID6441721DOI10.1111/j.1365-2362.1984.tb01211.xPepBankPUB-06441721

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialActivity measurement
In normal volunteers, VIP infusion significantly increased heart rate.
In plain wordsIn healthy volunteers, VIP infusion raised heart rate.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate in normal volunteers
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
Heart rate
62 beats min-1
controls, before VIP
Heart rate
75 beats min-1
controls, after VIP
Source sentences
Summary
Heart rate increased from 62 +/- 3 to 75 +/- 3 beats min-1 (P = 0.001) in controls and from 70 +/- 2 to 78 +/- 3 beats min-1 (P = 0.001) in hyperprolactinaemics.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172101
02HumanRandomized controlled trialActivity measurement
In patients with hyperprolactinaemia, VIP infusion significantly increased heart rate.
In plain wordsIn patients with high prolactin, VIP infusion raised heart rate.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate in hyperprolactinaemia
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
Heart rate
70 beats min-1
hyperprolactinaemics, before VIP
Heart rate
78 beats min-1
hyperprolactinaemics, after VIP
Source sentences
Summary
Heart rate increased from 62 +/- 3 to 75 +/- 3 beats min-1 (P = 0.001) in controls and from 70 +/- 2 to 78 +/- 3 beats min-1 (P = 0.001) in hyperprolactinaemics.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172102
03HumanRandomized controlled trialActivity measurement
In normal volunteers, VIP infusion significantly increased haematocrit.
In plain wordsIn healthy volunteers, VIP infusion raised haematocrit, the share of red cells in blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHaematocrit in normal volunteers
Study
n: not reported in source
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
Dose not stated
Measurements
Haematocrit
38%
controls, before VIP
Haematocrit
44%
controls, after VIP
Source sentences
Summary
Similarly, haematocrit increased from 38 +/- 2 to 44 +/- 1% (P = 0.001) and from 40 +/- 1 to 43 +/- 2% (P = 0.002) and plasma renin activity from 910 +/- 59 to a peak of 3344 +/- 282 pg ml-1 h-1 (P = 0.001) and from 1577 +/- 671 to a peak of 4954 +/- 1364 pg ml-1 h-1 (P = 0.001) in the two groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172103
04HumanRandomized controlled trialActivity measurement
In patients with hyperprolactinaemia, VIP infusion significantly increased haematocrit.
In plain wordsIn patients with high prolactin, VIP infusion raised haematocrit, the share of red cells in blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHaematocrit in hyperprolactinaemia
Study
n: not reported in source
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
Dose not stated
Measurements
Haematocrit
40%
hyperprolactinaemics, before VIP
Haematocrit
43%
hyperprolactinaemics, after VIP
Source sentences
Summary
Similarly, haematocrit increased from 38 +/- 2 to 44 +/- 1% (P = 0.001) and from 40 +/- 1 to 43 +/- 2% (P = 0.002) and plasma renin activity from 910 +/- 59 to a peak of 3344 +/- 282 pg ml-1 h-1 (P = 0.001) and from 1577 +/- 671 to a peak of 4954 +/- 1364 pg ml-1 h-1 (P = 0.001) in the two groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172104
05HumanRandomized controlled trialActivity measurement
In normal volunteers, VIP infusion significantly increased plasma renin activity.
In plain wordsIn healthy volunteers, VIP infusion raised renin activity in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma renin activity in normal volunteers
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Plasma renin activity
910 pg ml-1 h-1
controls, before VIP
Plasma renin activity
3344 pg ml-1 h-1
controls, peak
Source sentences
Summary
Similarly, haematocrit increased from 38 +/- 2 to 44 +/- 1% (P = 0.001) and from 40 +/- 1 to 43 +/- 2% (P = 0.002) and plasma renin activity from 910 +/- 59 to a peak of 3344 +/- 282 pg ml-1 h-1 (P = 0.001) and from 1577 +/- 671 to a peak of 4954 +/- 1364 pg ml-1 h-1 (P = 0.001) in the two groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172105
06HumanRandomized controlled trialActivity measurement
In patients with hyperprolactinaemia, VIP infusion significantly increased plasma renin activity.
In plain wordsIn patients with high prolactin, VIP infusion raised renin activity in the blood.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma renin activity in hyperprolactinaemia
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Plasma renin activity
1577 pg ml-1 h-1
hyperprolactinaemics, before VIP
Plasma renin activity
4954 pg ml-1 h-1
hyperprolactinaemics, peak
Source sentences
Summary
Similarly, haematocrit increased from 38 +/- 2 to 44 +/- 1% (P = 0.001) and from 40 +/- 1 to 43 +/- 2% (P = 0.002) and plasma renin activity from 910 +/- 59 to a peak of 3344 +/- 282 pg ml-1 h-1 (P = 0.001) and from 1577 +/- 671 to a peak of 4954 +/- 1364 pg ml-1 h-1 (P = 0.001) in the two groups, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172106
07HumanRandomized controlled trialActivity measurement
In normal volunteers, VIP infusion significantly increased prolactin concentrations.
In plain wordsIn healthy volunteers, VIP infusion raised blood prolactin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseProlactin in normal volunteers
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Prolactin
134 mU 1(-1)
controls, before VIP
Prolactin
377 mU 1(-1)
controls, peak
Source sentences
Summary
Prolactin concentrations rose in the control group only, from 134 +/- 11 to a peak of 377 +/- 35 mU 1(-1) (P = 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172107
08HumanRandomized controlled trialActivity measurement
In patients with hyperprolactinaemia, prolactin showed little change during VIP infusion.
In plain wordsIn patients with high prolactin, VIP infusion caused little change in prolactin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeProlactin in hyperprolactinaemia
Study
n: not reported in source
Outcome group
Hormone levels · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Prolactin
3873 mU 1(-1)
hyperprolactinaemics, before VIP
Prolactin
3998 mU 1(-1)
hyperprolactinaemics, peak
Source sentences
Summary
whilst in the hyperprolactinaemics little change occurred from the pre-infusion concentration of 3873 +/- 2179 reaching a peak of 3998 +/- 2347 mU 1(-1) (P greater than 0.07).
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
Report a problemFND-0644172108

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

09HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism
In normal subjects, dexamethasone pretreatment did not alter any parameter of the response to VIP.
In plain wordsIn healthy people, dexamethasone pretreatment did not change the body's response to VIP infusion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP response after dexamethasone pretreatment
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Dexamethazone did not alter any parameter of the response to VIP.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0644172109
10HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism
In normal subjects, bromocriptine pretreatment did not affect the heart rate response to VIP.
In plain wordsIn healthy people, bromocriptine pretreatment did not change the heart rate response to VIP infusion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHeart rate response to VIP after bromocriptine
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Bromocriptine did not affect the heart rate, haematocrit or renin response to VIP but clearly inhibited the rise in prolactin which remained at unmeasurable concentrations throughout the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0644172110
11HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism
In normal subjects, bromocriptine pretreatment did not affect the haematocrit response to VIP.
In plain wordsIn healthy people, bromocriptine pretreatment did not change the haematocrit response to VIP infusion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeHaematocrit response to VIP after bromocriptine
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Cardiovascular
Source sentences
Summary
Bromocriptine did not affect the heart rate, haematocrit or renin response to VIP but clearly inhibited the rise in prolactin which remained at unmeasurable concentrations throughout the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0644172111
12HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism
In normal subjects, bromocriptine pretreatment did not affect the renin response to VIP.
In plain wordsIn healthy people, bromocriptine pretreatment did not change the renin response to VIP infusion.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeRenin response to VIP after bromocriptine
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
Bromocriptine did not affect the heart rate, haematocrit or renin response to VIP but clearly inhibited the rise in prolactin which remained at unmeasurable concentrations throughout the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0644172112
13HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneRandomized controlled trialMechanism
In normal subjects, bromocriptine pretreatment clearly inhibited the prolactin rise caused by VIP.
In plain wordsIn healthy people, bromocriptine pretreatment blocked the rise in prolactin that VIP infusion caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseProlactin response to VIP after bromocriptine
Study
n: not reported in source
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
but clearly inhibited the rise in prolactin which remained at unmeasurable concentrations throughout the infusion.
1 context sentence(design, population, supporting numbers)
Summary · context
Vasoactive intestinal polypeptide (VIP) was infused into normal volunteers and patients with hyperprolactinaemia.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0644172113

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.